These encouraging data have led to the initiation of clinical studies in lung cancer, evaluating the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab, an anti-VEGF antibody (Herbst et al, 2005). Here, VEGFA is linked to lung cancer.